References
1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rT-PA stroke study group. N Engl J Med 1995;333:1581-1587.
2. Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
3. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005;36:1232-1240.
4. Adeoye O, Hornung R, Khatri P, et al. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
5. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.
6. Majersik JJ, Meurer WJ, Frederiksen SA, et al. Observational study of telephone consults by stroke experts supporting community tissue plasminogen activator delivery. Acad Emerg Med 2012;19:E1027-E1034.
7. Pervez MA, Silva G, Masrur S, et al. Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke 2010;41:e18-e24.
8. Tekle WG, Chaudhry SA, Hassan AE, et al. Drip-and-ship thrombolytic treatment paradigm among acute ischemic stroke patients in the United States. Stroke 2012;43:1971-1974.
9. Mansoor S, Zand R, Al-Wafai A, et al. Safety of a ‘‘drip and ship’’ intravenous thrombolysis protocol for patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:969-971.
10. Qureshi AI, Chaudhry SA, Rodriguez GJ, et al. Outcome of the ‘drip-and-ship’ paradigm among patients with acute ischemic stroke: results of a statewide study. Cerebrovasc Dis Extra 2012;2:1-8.
11. Martin-Schild S, Morales MM, Khaja AM, et al. Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe? J Emerg Med 2011;41:135-141.
12. Silverman IE, Beland DK, Chhabra J, et al. The ‘‘drip-and-ship’’ approach: starting IV t-PA for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center. Conn Med 2005;69:613-620.
13. Hsia AW, Edwards DF, Morgenstern LB, et al. Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study. Stroke 2011;42:2217-2221.
14. Karve SJ, Balkrishnan R, Mohammad YM, et al. Racial/ethnic disparities in emergency department waiting time for stroke patients in the United States. J Stroke Cerebrovasc Dis 2011;20:30-40.
15. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 2007;38:414-416.
16. American Community Survey, 2009-2011 American Community Survey 3-Year Estimates.
www.nhgis.org. Accessed May 2, 2014.
17. Howard VJ, Acker J, Gomez CR, et al. An approach to coordinate efforts to reduce the public health burden of stroke: The Delta States Stroke Consortium. Prev Chronic Dis 2004;1:A19.
19. Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol 2001;54:343-349.
20. Siegler JE, Boehme AK, Albright KC, et al. Ethnic disparities trump other risk factors in determining delay to emergency department arrival in acute ischemic stroke. Ethn Dis 2013;23:29-34.
21. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
22. Wolf PA, D’Agostino RB, O’Neal MA, et al. Secular trends in stroke incidence and mortality. The Framingham study. Stroke 1992;23:1551-1555.
23. Howard VJ, Lackland DT, Lichtman JH, et al. Care seeking after stroke symptoms. Ann Neurol 2008;63:466-472.
24. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210YS216.
25. Longstreth WT Jr, Katz R, Tirschwell DL, et al. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med 2010;28:359-363.
26. Centers for Disease Control and Prevention. Prevalence of stroke--United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012;61:379-382.
27. Zanaty M, Chalouhi N, Starke RM, et al. Epidemiology of a large telestroke cohort in the Delaware Valley. Clin Neurol Neurosurg 2014;125:143-147.
28. Adeoye O, Haverbusch M, Woo D, et al. Is ED disposition associated with intracerebral hemorrhage mortality? Am J Emerg Med 2011;29:391-395.
29. Schwamm LH, Reeves MJ, Pan W, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010;121:1492-1501.
30. Adams R, Acker J, Alberts M, et al. Recommendations for improving the quality of care through stroke centers and systems: an examination of stroke center identification options: multidisciplinary consensus recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. Stroke 2002;33:e1-e7.